Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The user has been on finasteride for 7 years and had a hair transplant, but is experiencing hair thinning and itchiness, particularly on one side, leading to concerns about male pattern baldness or other health issues. Despite having a full head of hair, the user is considering shaving it due to mental health struggles and is advised to consult a therapist and consider other treatments like minoxidil or dutasteride.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

A 19-year-old is using oral dutasteride, topical minoxidil, and dermastamping to address hair loss and enhance facial hair growth, experiencing minimal side effects and increased body hair. They report positive results in hairline thickness and temple closure.

A 20-year-old is experiencing positive results with oral minoxidil 2.5mg and oral finasteride 1mg after 1.5 months, noticing thicker hair but still shedding. They also mention eating a lot of protein to aid hair growth.

The user is experiencing hair regrowth after using a regimen of 2.5mg minoxidil, 0.5mg dutasteride, 1mg biotin daily, micro-needling weekly, and nizoral every three days. Other users confirm seeing signs of regrowth and encourage the user to remain optimistic.

A 17-year-old male using Minoxidil and Finasteride for hair regrowth sees vellus hairs and plans to start oral treatments at 18. Concerns about using Finasteride during puberty are discussed, with suggestions to wait until fully matured.

A 22-year-old started taking finasteride at 20 to combat hair loss, experiencing significant shedding initially but no side effects. Despite challenges in obtaining dutasteride and oral minoxidil in Sweden, the user is content with the current hairline and considering additional treatments like microneedling.

The user experienced significant hair regrowth using 1mg oral finasteride daily and topical minoxidil every other day, with plans to switch to oral minoxidil for consistency. They reported initial shedding and minor side effects, which resolved over time.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

Finasteride can increase body and facial hair growth due to increased testosterone, despite its intended use to reduce hair loss on the scalp. Some users consider trying topical finasteride for less systemic impact, while others report mixed results and side effects.

The conversation discusses increasing the dose of oral minoxidil from 2.5mg to 5mg for better hair density, with concerns about potential side effects like heart rate changes and fluid retention. Users suggest consulting a doctor, considering individual tolerance, and exploring other treatments like dutasteride.

An 18-year-old experiencing hair loss seeks a finasteride prescription but faces skepticism from doctors who only recommend vitamins. A suggestion is made to consult a dermatologist for a proper diagnosis and potential treatment with finasteride or minoxidil.

An 18-year-old started taking finasteride for early-stage hair loss, prescribed by a dermatologist who advised against waiting due to potential follicle loss. The conversation includes differing opinions on starting finasteride early, with some users sharing personal experiences and concerns about potential side effects.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

Using finasteride may slow beard growth due to reduced DHT, but minoxidil can enhance beard growth. Some users report slower beard growth on finasteride, while others see continued improvement with minoxidil.

A new alcohol-free, propylene glycol-free topical finasteride foam is available for prescription in Canada and the USA, offering a cleaner alternative for hair loss treatment. The product also offers a combination of 0.1% finasteride with 5% minoxidil and aims to be affordable and less irritating for sensitive scalps.

Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

Finasteride and dutasteride have potential risks, including post-finasteride syndrome, but are commonly used for hair loss. RU58841, minoxidil, and needling are suggested as alternatives, though all treatments carry risks.

The user is considering switching to topical finasteride or pyrilutamide to stabilize hair loss before a hair transplant, currently using oral minoxidil and finasteride. Suggestions include sticking to the current regimen as it is already potent, and caution against using pyrilutamide from unreliable sources.

The user maintained hair with finasteride for 4.5 years and noticed some progress with dutasteride after 6 months, experiencing reduced chest and facial hair. They did not use minoxidil and reported no side effects from either treatment.

Continue using finasteride and minoxidil for hair loss, as better treatments like Breezula, Pyrilutamide, and PP405 are being developed. These future solutions promise fewer side effects and improved results.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.